Matinas Biopharma Holdings, Inc. (AMEX:MTNB) shares are trading higher after the company announced complete clinical resolution of a patient's recurrent hemorrhagic cystitis following treatment with MAT2203. The patient was treated under Matinas' Expanded Access/Compassionate Use Program. The company's shares are moving on very heavy trading volume, with more than 197 million shares traded in the session, far exceeding the stock's 100-day average of 1.146 million shares. The shares are up 113% at 33 cents at the time of publication.